Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

pine group, 52.9 percent in the olanzapine group, and 36.2 percent in the placebo group. The most commonly reported adverse events (greater than or equal to 5 percent and twice the rate of placebo) with asenapine included sedation, dizziness, somnolence, oral hypoesthesia (numbness) and weight increase.

Presentation of the overview of the Olympia Program in bipolar I disorder (oral abstract #44) was on Tuesday, May 6, at 12:00 pm in Room 151A.

Olympia Data: Schizophrenia

The schizophrenia program includes four placebo- and active-controlled, six-week trials involving more than 1,300 patients with schizophrenia. In two of the trials involving almost 700 patients, asenapine produced 19- to 20-point reductions in Positive and Negative Syndrome Scale (PANSS) total score and was significantly superior to placebo. PANSS total score is a measure of positive symptoms (e.g., hallucinations and delusions), negative symptoms (such as lack of emotional expression), and general psychopathology symptoms (such as anxiety and depression).

The third study in approximately 260 patients was considered a failed trial as neither asenapine nor the active control olanzapine differentiated from placebo. A fourth trial of approximately 400 patients with acute schizophrenia was considered a negative trial, as the active-control (olanzapine) differentiated from placebo whereas asenapine did not.

The most commonly reported AEs (greater than or equal to 5 percent and twice the rate of placebo) among patients taking asenapine in the short-term schizophrenia trials were somnolence, akathisia (restlessness) and oral hypoesthesia (numbness).

"Schizophrenia is a lifelong illness that requires ongoing treatment to effectively manage the spectrum of symptoms that patients suffer from. As such, new treatments need to demonstrate an acceptable long-term safety profile," said Steven Potkin, M.D., Professor, Department of Psychiatry and Human Behavior, University
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... studies of its NeuroFlo(TM) ... Ischemic Stroke, MINNEAPOLIS, April 1, 2008 CoAxia(TM), ... an additional $11.5M financing,from current investors to support the ... extension of the previously announced,C Round and will allow ...
... 1, 2008 CV Therapeutics, Inc.,(Nasdaq: CVTX ... 57th Annual,Scientific Sessions of the American College of ... reduced the,risk of recurrent ischemia (p=0.002), worsening angina ... patients,(n=3,565) in the MERLIN- TIMI 36 study., ...
Cached Medicine Technology:CoAxia(TM) Announces $11.5M Equity Financing From Existing Investors 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 2CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina 3
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... a way to predict whether women with ductal carcinoma in ... cancer are at risk of developing more invasive tumors ... women with DCIS will have the opportunity to be more ... will have much more information, so they can better know ...
... for Radiation Oncology (ASTRO) has released its Emerging ... body radiotherapy (SBRT) in lung cancer treatment. SBRT ... focused radiation beams to target a well-defined tumor ... planning and precise treatment setup to deliver the ...
... release is available in French . , Ottawa, ... ideas amongst researchers is a fundamental element in turning knowledge ... Thanks to the newly launched PubMed Central Canada (PMC Canada), ... archive of published Canadian health research. PMC Canada ...
... researchers find , WEDNESDAY, April 28 (HealthDay News) -- ... lung disease caused by cystic fibrosis: Which comes first, ... beginning to answer that question, and it looks like ... an assistant professor of internal medicine at the University ...
... ... Air” in HuffPost Living , ... (PRWEB) April 28, 2010 -- Huffington Post blogger and radio host Kathleen ... radio program, The Kathleen Show ., , ,Each week in The Huffington Post ...
... ... , ... 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and ... care programs in connection with its marketing and promotional practices for the blockbuster atypical ...
Cached Medicine News:Health News:Breakthrough method predicts risk of invasive breast cancer 2Health News:Breakthrough method predicts risk of invasive breast cancer 3Health News:Canada joins international network providing free access to health research 2Health News:Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease 2Health News:The Kathleen Show Launches Weekly Audio Blog on The Huffington Post 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 3
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
... designed to enhance the chin contour, this chin ... a high-profile central chin projection. Symmetrical Chin ... this implant provides a high central projection, as ... Cleft Chin Implants - Designed with a unique ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
... IEC CL31 Multispeed Series offers unsurpassed ... quiet, compact, 1.2 liter benchtop centrifuge. ... and accessories and high-speed centrifugation capabilities, ... everything you need to meet a ...
Medicine Products: